Stem Cells for Autism Patient on News
Medistem Licensee Featured on Miami's FOX News Station for Treatment of Autism Patient
Thursday September 27, 8:05 am ET
Autism Patient's Story Highlights Promise of Adult Stem Cell Therapies
http://youtube.com/watch?v=cdeI9ZYkvIg
SCOTTSDALE, AZ--(MARKET WIRE)--Sep 27, 2007 -- Medistem Laboratories (OTC BB:MDSM.OB - News) (Frankfurt:S2U.F - News) announced today that its licensee, Institute of Cellular Medicine (www.cellmedicine.com) was the focus of a recent medical report on (WSVN-TV) Miami's Fox news station highlighting success in adult stem cell therapy in autism. The story, titled "All for Autism" follows the journey of Patricia Cabrera, an autistic 7 year old who after finding no success with other treatments received adult stem cell therapy from the Institute of Cellular Medicine (ICM) and has made significant improvements.
The news story and video can be accessed at http://youtube.com/watch?v=cdeI9ZYkvIg.
"While Medistem is not formally conducting clinical trials in the area autism at this point, anecdotal cases such as this one provide rationale for our continued exploratory interest in this therapeutic area," said Thomas Ichim, Medistem's Chief of Scientific Development. He continued, "Being a licensee of Medistem, data generated from clinical cases such as these are incorporated into our company's IP portfolio, which allows a type of strategic positioning that is to our knowledge unique in this area."
About Medistem Laboratories, Inc.
Medistem Laboratories is a biotechnology company that discovers, develops, and commercializes adult stem cell products that address serious medical conditions. While drug discovery and development is its primary focus, Medistem has compiled a body of proprietary technologies it outlicenses to commercial entities in markets where stem cell administration is permissible. Due to its licensee relationships and collaborative efforts with respected institutions, Medistem believes it is well positioned to be a leading developer of adult stem cell products.
Cautionary Statement
This document does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This document contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may include projections of matters that affect revenue, the ability to develop or license certain technologies; operating expenses or net earnings; projections of capital expenditures; projections of growth; hiring plans; plans for future operations; financing needs or plans; plans relating to the company's products and services; and assumptions relating to the foregoing.
Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information.
Some of the important factors that could cause the company's actual results to differ materially from those projected in forward-looking statements made by the company include, but are not limited to, the following: technology development limitations, intense competition, risk of business interruption, management of rapid growth, need for additional financing, regulatory approvals and requirements, dependence on key personnel and research, management and other administrative costs.
These factors are discussed in greater detail in the company's quarterly and annual periodic reports, all as filed with the Securities and Exchange Commission.
Contact:
Medistem Laboratories, Inc.
Chris McGuinn
602-318-3535
http://www.medisteminc.com
Social & Bookmarking:
2 Comments | Add Comment
John Rudolph said...
From previous press releases it seems that Medistem has IP on the use of stem cells for autism.
This possible treatment approach has a market in the billions if a proper autism stem cell business model is set up.
Add Comment
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.
Jill Strackan said...
I have seen this work before, the group published the theory behind it in the Journal of Translational Medicine. Its interesting how quickly some research can be "translated" if all the figures are together and in line.